secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2026-08-11T12:26:13+00:00
Accession:  0001193125-26-343519
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mereo Q2 net loss narrows to $7M; Sentynl alvelestat option deal worth up to $475M
--------------------------------------------------------------------------------

- Q2 2026 net loss $7.0M vs $14.6M in Q2 2025; R&D down $3.6M to $1.8M.
- Cash $30.1M at June 30, 2026; runway into late-2027, excluding $40M option exercise payment.
- Sentynl (Zydus sub) option for alvelestat U.S. rights: $40M upfront/R&D on exercise, up to $435M milestones, double-digit royalties.
- Setrusumab Phase 3 missed primary fracture endpoint but hit key secondary BMD and PRO endpoints; FDA/MHRA discussions ongoing.
- Phase 3 alvelestat trial planned for early 2027 if option exercised.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000119312526343519/0001193125-26-343519-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000119312526343519/mreo-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-343519

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer